Improved Detection of preclinical Colorectal Liver Metastases by High Resolution Ultrasound including Molecular Ultrasound Imaging using the targeted Contrast Agent BR55

C. Hackl; D. Schacherer; M. Anders; L. M. Wiedemann; A. Mohr; H. J. Schlitt; C. Stroszczynski; F. Tranquart; E. M. Jung

doi:10.1055/s-0041-111838

Ultraschall in der Medizin - European Journal of Ultrasound, Inhaltsverzeichnis

Ultraschall Med 2016; 37(03): 290-296
DOI: 10.1055/s-0041-111838

Rapid Communication

Improved Detection of preclinical Colorectal Liver Metastases by High Resolution Ultrasound including Molecular Ultrasound Imaging using the targeted Contrast Agent BR55

Verbesserte Detektion präklinischer kolorektaler Lebermetastasen durch hochauflösenden Ultraschall und Molekulares Imaging durch das gezielt bindende Kontrastmittel BR55

C. Hackl

¹Surgery, University Hospital Regensburg, Germany

,

D. Schacherer

²Internal Medicine I, University Hospital Regensburg, Germany

,

M. Anders

¹Surgery, University Hospital Regensburg, Germany

,

L. M. Wiedemann

¹Surgery, University Hospital Regensburg, Germany

,

A. Mohr

³Internal Medicine II, University Hospital Regensburg, Germany

,

H. J. Schlitt

¹Surgery, University Hospital Regensburg, Germany

,

C. Stroszczynski

⁴Radiology, University Hospital Regensburg, Germany

,

F. Tranquart

⁵Geneva Research Center and Manufacturing Site, Bracco Suisse SA, Geneva, Switzerland

,

E. M. Jung

⁴Radiology, University Hospital Regensburg, Germany

› Institutsangaben

Abstract

Purpose: Aim of the present study was to investigate the sensitivity of high resolution ultrasound (HRU), standard contrast-enhanced ultrasound (CEUS) and CEUS using a novel vascular endothelial growth factor receptor 2 (VEGFR2)-targeted contrast agent for the detection of hepatic metastases in a mouse model of colorectal cancer using clinical standard technology.

Materials and Methods: The human colon cancer cell line HT29, transfected with luciferase cDNA for in vivo bioluminescence monitoring, was injected intrasplenically into CB17.SCID mice. Mice were monitored weekly by bioluminescence and after 2 and 4.5 weeks by HRU and CEUS. Contrast media (untargeted BR1, targeted BR55) was applied and digital cine loops from the arterial phase (15 – 45 sec), portal venous phase (50 – 120 s) and late phases (3 – 5 min, 1hour) of the whole liver were analyzed. Data were correlated with postmortem histopathology.

Results: Without contrast enhancement, lesions > 4 mm were reliably detected. After use of untargeted CEUS, lesions > 2 mm were reliably detected and enhanced rim vascularization and late-phase wash-out was shown. With BR55, lesions > 0.8 mm were reliably detected with excellent documentation of vascularization. A persistent contrast enhancement was seen > 30 min after injection. Contrast-enhancement patterns with BR55 significantly correlated with CD31 (R2 = 0.74) and VEGFR2-immunohistochemistry (R2 = 0.66).

Conclusion: Detection of metastases by HRU and CEUS was earlier and more accurate than monitoring via bioluminescence. In vivo monitoring of hepatic micrometastases can thus be performed without prior modification of cancer cells using standard technology.

Zusammenfassung

Ziel: Ziel der vorliegenden Studie war die Bestimmung der Sensitivität hochauflösender Sonografie, standardisierter kontrastverstärkter Sonografie und kontrastverstärkter Sonografie mittels eines den vaskulären endothelialen Wachstumsfaktor-Rezeptor 2 (VEGFR2) gezielt bindenden Ultraschallkontrastmittels in der Detektion hepatischer Metastasen im präklinischen Mausmodell des Kolonkarzinoms mithilfe klinischer Standardtechnologie.

Material und Methoden: Die humane Kolonkarzinomzelllinie HT29, transfiziert mit Luciferase cDNA zur Ermöglichung eines Biolumineszenz-Monitorings, wurde intrasplenisch in CB17.SCID Mäuse injiziert. Es erfolgten wöchentliche Biolumineszenzmessungen sowie Ultraschalluntersuchungen nach 2 und 4,5 Wochen. Als Kontrastmittel kamen BR1 und gezieltes BR55 zur Anwendung. Videosequenzen der arteriellen Phase (15 – 45 s), der portalvenösen (50 – 120 s), und zweier Spätphasen (3 – 5 min, 1 h) der gesamten Leber wurden analysiert. Die Ultraschallergebnisse wurden mit postmoraler Histologie korreliert.

Ergebnisse: Hochauflösende Sonografie ohne Kontrastmittel konnte hepatische Metastasen > 4 mm reproduzierbar detektieren. Mithilfe von BR1-Kontrastverstärkung wurden Metastasen > 2 mm zuverlässig detektiert, zudem eine verstärkte Randperfusion und Spätphasen-washout nachgewiesen. Mit BR55 konnten Metastasen ab 0,8 mm detektiert werden mit exzellenter Dokumentation der Vaskularisation. Zudem wurde hier in den Metastasen eine persistente Kontrastmittelanreicherung auch > 30 min nach Injektion detektiert. Die Kontrastmittelverteilung von BR55 korrelierte signifikant mit der Immunhistochemie für CD31 (R2 = 0,74) und VEGFR2 (R2 = 0,66).

Schlussfolgerung: Die Metastasendetektion mittels hochauflösender und kontrastverstärkter Sonografie erfolgte früher und akkurater als mittels Biolumineszenz. Somit kann ein in vivo monitoring hepatischer Metastasen in diesem Modell zukünftig auch ohne zuvor nötige Zellalteration und unter Anwendung klinischer Standardtechnologie erfolgen.

Key words

abdomen - blood vessels - ultrasound

Volltext

Referenzen

References
1 Cantisani V, Ricci P, Erturk M et al. Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue(R) low mechanical index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. Ultraschall in der Medizin 2010; 31: 500-505
2 Claudon M, Dietrich CF, Choi BI et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver – update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound in medicine & biology 2013; 39: 187-210
3 Tardy I, Pochon S, Theraulaz M et al. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Investigative radiology 2010; 45: 573-578
4 Hyvelin JM, Tardy I, Arbogast C et al. Use of ultrasound contrast agent microbubbles in preclinical research: recommendations for small animal imaging. Investigative radiology 2013; 48: 570-583
5 Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936
6 Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. Journal of biochemistry and molecular biology 2006; 39: 469-478
7 Grouls C, Hatting M, Rix A et al. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment. Radiology 2013; 267: 487-495
8 Zhang L, Hellstrom KE, Chen L. Luciferase activity as a marker of tumor burden and as an indicator of tumor response to antineoplastic therapy in vivo. Clinical & experimental metastasis 1994; 12: 87-92
9 Pochon S, Tardy I, Bussat P et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Investigative radiology 2010; 45: 89-95
10 Willmann JK, Paulmurugan R, Chen K et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246: 508-518
11 Willmann JK, Cheng Z, Davis C et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008; 249: 212-219
12 Sugimoto K, Moriyasu F, Negishi Y et al. Quantification in molecular ultrasound imaging: a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft. Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine 2012; 31: 1909-1916
13 Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69: 4-10
14 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
15 Welti J, Loges S, Dimmeler S et al. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. The Journal of clinical investigation 2013; 123: 3190-3200
16 Recondo Jr G, Diaz-Canton E, de la Vega M et al. Advances and new perspectives in the treatment of metastatic colon cancer. World Journal of Gastrointestinal Oncology 2014; 6: 211-224
17 Francia G, Emmenegger U, Lee CR et al. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther 2008; 7: 3452-3459
18 Hackl C, Man S, Francia G et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 2013; 62: 259-271
19 Dietrich CF, Ignee A, Trojan J et al. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 2004; 53: 401-405
20 Strobel DSK, Blank W, Schuler A et al. DEGUM-Multizenterstudie zur Kontrastmittelsonografie bei B-Bild-morphologisch unklarer Leberraumforderungen: Wie oft sind die tumortypischen Vaskularisationsmuster nachweisbar?. Ultraschall in der Medizin 2008; 29